Source: Virtual Congress 2021 – Treatments for airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Kahnert (Munich, Germany), R. Jörres (Munich, Germany), F. Trudzinski (Heidelberg, Germany), P. Alter (Marburg, Germany), C. Kellerer (Munich, Germany), H. Watz (grosshansdorf, Germany), T. Welte (Hannover, Germany), R. Bals (Homburg, Germany), D. Kauffmann-Guerrero (Munich, Germany), J. Behr (Munich, Germany), R. Holle (Munich, Germany), C. Vogelmeier (Munich, Germany), J. Lutter (Munich, Germany). Treatment with inhaled corticosteroids in COPD groups GOLD A and B –relationship to clinical state in the COSYCONET cohort. 1836

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of an inhaled corticosteroid/long-acting ?2-agonist combination in symptomatic COPD patients in GOLD groups B and D Source: Eur Respir J 2015; 46: 255-258 Year: 2015 Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 A new user cohort study comparing the risk of pneumonia in inhaled corticosteroid (ICS) vs. long-acting bronchodilator (LABD) regimens in COPD Source: Annual Congress 2013 –Risk factors for COPD and lung function decline Year: 2013 Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011? Source: Eur Respir J 2014; 43: 1201-1203 Year: 2014 Once-daily QVA149 improves lung function and health status versus twice-daily salmeterol/fluticasone (SFC) in symptomatic GOLD B and GOLD D COPD patients: LANTERN/ILLUMINATE pooled analysis Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Estimation of tiotropium efficacy at the COPD patients with group D Source: International Congress 2015 – Different data in COPD Year: 2015 Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Eligibility of patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Pneumonia risk in COPD patients on long term inhaled corticosteroids – Data from the European COPD audit<% Source: Annual Congress 2013 –Guidelines and exacerbations Year: 2013 The adherence to inhaled drugs in COPD patients: Effect on survival Source: International Congress 2015 – Treatment and control of respiratory disease Year: 2015 GLISTEN Study subanalysis: Glycopyrronium differentially improves lung function, health status and rescue medication use when added to salmeterol/fluticasone in COPD severity groups Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Once-daily indacaterol 150µg or 300µg and other bronchodilators in COPD patients of GOLD 2011 groups A and B Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the SHINE study Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Effect of aclidinium bromide on dyspnoea and health status in patients with stable COPD: Phase III data by GOLD 2013 classification Source: International Congress 2014 – Asthma and COPD management Year: 2014 Impact of the GOLD 2011 guidelines on treatment regimens in COPD patients Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015